Bioasis is breaking down a literal barrier to better neurological disease treatments

Market Trends

English - November 15, 2021 14:00 - 7 minutes - 10.1 MB
Investing Business News Business News stockmarket investing investment Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Cassiar’s gold fever is breathing new life in a historic gold district

Next Episode: New Placer has hit their stride with a clear path ahead

Deborah Rathjen, Executive Chair of Bioasis Technologies Inc. (TSXV: BTI | OTCQB: BIOAF), highlights the company’s xB3 platform which is being developed to treat patients who suffer from a variety of central nervous system disorders.

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.